今天，我们公布了 2026 年第二季度财务业绩。在财报电话会议上，首席执行官 Kyle Gano 讨论了 Neurocrine 的三款首创药物如何为业内最强的晚期神经科学管线之一提供资金支持，我们正专注于帮助患有严重且未被充分关注疾病的人群。 更多内容请见我们的财报新闻稿：https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-reports-second-quarter-2026-financial
Today, we announced our Q2 2026 financial results. During our earnings call, Chief Executive Officer Kyle Gano discussed how Neurocrine’s three first-in-class medicines are funding one of the industry’s strongest late-state neuroscience pipelines as we focus on helping people living with serious, under-addressed diseases.
Read more in our earnings press release: https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-reports-second-quarter-2026-financial
来源：Neurocrine Biosciences · x.com